Urofollitropin

Two year agreement for dedicated representative orthopedic specialty team

SADDLE RIVER, N.J., Sept. 28 /PRNewswire-FirstCall/ -- PDI, Inc. a diversified sales and marketing services provider to the biopharmaceutical and medical devices and diagnostics industries, today announced that it has been selected by Ferring Pharmaceuticals, Inc. to provide a dedicated representative sales team in support of EUFLEXXA(TM).

EUFLEXXA(TM) is the first and only non-avian-derived biologic formulation of hyaluronic acid approved in the U.S. for osteoarthritis of the knee. The PDI sales team will be promoting the product to orthopedic specialists. The agreement, which runs between October 1, 2005 and September 30, 2007, represents approximately $17 million to $18 million in potential revenue to PDI over the two year program. This new business win is one of the three new business wins referenced in PDI's second quarter 2005 conference call on August 9th.

Steve Budd, President of PDI said, "Ferring's fertility products group has been a client of ours for nearly 8 years. We are proud of the work we have done for them over the term of our relationship. Being selected by Ferring to support the launch of EUFLEXXA(TM) to orthopedic specialists validates our ability to bring long term value to our clients with specialty products."

Charles Saldarini, Vice Chairman and CEO of PDI, said, "Ferring evaluated its sales force options for launching EUFLEXXA(TM) and determined that PDI was the best choice because of the flexibility of our service, our responsiveness to Ferring's needs and our expertise in launching and maintaining specialty sales forces. Having worked with PDI over the last several years, Ferring knows we can execute."

About PDI

PDI, Inc. is a diversified sales and marketing services provider to the biopharmaceutical and medical devices and diagnostics industries. PDI's comprehensive set of sales and marketing solutions is designed to increase its clients' strategic flexibility and enhance their efficiency and profitability. Headquartered in Saddle River, NJ, PDI also has offices in Pennsylvania and Illinois.

PDI's sales and marketing services include dedicated contract sales, Select Access(TM), our targeted sales solution that leverages an existing infrastructure, clinical sales teams; marketing research and consulting; and medical education and communications. The company's experience extends across multiple therapeutic categories and includes office and hospital-based initiatives.

PDI's commitment is to deliver innovative solutions, unparalleled execution and superior results for its clients. Through strategic partnership and client-driven innovation, PDI maintains some of the longest standing sales and marketing relationships in the industry. Recognized as an industry pioneer, PDI remains committed to continued innovation.

For more information, visit the Company's website at http://www.pdi-inc.com/ .

About Ferring Pharmaceuticals

Ferring Pharmaceuticals Inc., part of the Ferring Group, a privately owned, international pharmaceutical company, markets Menopur(R) (menotropins for injection, USP), Bravelle(R) (urofollitropin for injection, purified), Repronex(R) (menotropins for injection, USP) and Novarel(R) (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. Ferring also offers the Q-CAP(TM), the first and only needle- free reconstitution device, for use with its fertility treatments. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility.

This press release contains forward-looking statements regarding future events and financial performance. These statements involve a number of risks and uncertainties and are based on numerous assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond PDI's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, changes in our operating expenses, adverse patent rulings, FDA, legal or accounting developments, competitive pressures, failure to meet performance benchmarks in significant contracts, changes in customer and market requirements and standards, the impact of any stock repurchase programs, and the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's Annual Report on Form 10-K for the year ended December 31, 2004, and PDI's periodic reports on Form 8-K filed with the Securities and Exchange Commission since January 1, 2005. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACT: Stephen P. Cotugno, Executive Vice President-Corporate Development, PDI, Inc., +1-201-574-8617

Web site: http://www.pdi-inc.com/ http://www.ferringusa.com/

COPYRIGHT 2005 PR Newswire Association LLC
COPYRIGHT 2005 Gale Group